Table 1.
Cohort characteristics when stratified by year of treatment.
| SACT Patients | SACT | SACT | ||
|---|---|---|---|---|
| (n = 4569) | 2019 | 2020 | ||
| (n = 2449) | (n = 2120) | |||
| n | % | n | % | |
| Sex | ||||
| Male | 1122 | 45.80 | 933 | 44.00 |
| Female | 1327 | 54.20 | 1187 | 56.00 |
| Age | ||||
| <50 | 436 | 17.80 | 387 | 18.30 |
| 50–59 | 541 | 22.10 | 499 | 23.50 |
| 60–69 | 683 | 27.90 | 607 | 28.60 |
| 70–79 | 603 | 24.60 | 477 | 22.50 |
| ≥80 | 186 | 7.60 | 150 | 7.10 |
| Mean (SD) | 62.50 (13.20) | 61.80 (13.00) | ||
| SES | ||||
| Low | 2043 | 83.40 | 1804 | 85.10 |
| Medium | 69 | 2.80 | 41 | 1.90 |
| High | 246 | 10.00 | 185 | 8.70 |
| Missing | 91 | 3.70 | 90 | 4.20 |
| Ethnicity | ||||
| White British | 1171 | 47.80 | 831 | 39.20 |
| White Other | 191 | 7.80 | 172 | 8.10 |
| Black Caribbean | 117 | 4.80 | 74 | 3.50 |
| Black African | 94 | 3.80 | 96 | 4.50 |
| Black Other | 56 | 2.30 | 50 | 2.40 |
| Asian | 64 | 2.60 | 51 | 2.40 |
| Mixed | 30 | 1.20 | 23 | 1.10 |
| Other | 66 | 2.70 | 43 | 2.00 |
| Unknown | 660 | 26.90 | 780 | 36.80 |
| Tumour Type | ||||
| Urological | 534 | 21.80 | 456 | 21.50 |
| Gynaecological | 185 | 7.60 | 174 | 8.20 |
| Gastrointestinal | 565 | 23.10 | 418 | 19.70 |
| Skin/Head and Neck | 153 | 6.20 | 142 | 6.70 |
| CNS | 93 | 3.80 | 62 | 2.90 |
| Breast | 595 | 24.30 | 571 | 26.90 |
| Lung | 281 | 11.50 | 275 | 13.00 |
| Other | 43 | 1.80 | 22 | 1.00 |
| Stage | ||||
| 1 | 119 | 4.90 | 69 | 3.30 |
| 2 | 242 | 9.90 | 186 | 8.80 |
| 3 | 448 | 18.30 | 301 | 14.20 |
| 4 | 1529 | 62.40 | 1527 | 72.00 |
| Missing | 111 | 4.50 | 37 | 1.70 |
| SACT Type | ||||
| Chemotherapy | 1027 | 41.90 | 725 | 34.20 |
| Immunotherapy | 157 | 6.40 | 208 | 9.80 |
| Biological/Targeted | 911 | 37.20 | 806 | 38.00 |
| Combo Biological/Targeted | 126 | 5.10 | 210 | 9.90 |
| Combined Chemo | 206 | 8.40 | 145 | 6.80 |
| Combined Immunotherapy | 22 | 0.90 | 26 | 1.20 |
| Treatment Paradigm | ||||
| Neoadjuvant | 203 | 8.30 | 176 | 8.30 |
| Adjuvant | 503 | 20.50 | 418 | 19.70 |
| Radical | 100 | 4.10 | 14 | 0.70 |
| Palliative | 1630 | 66.60 | 1453 | 68.50 |
| Curative | 13 | 0.50 | 59 | 2.80 |
| Line of Palliative Treatment (2019, n = 1630; 2020, n = 1453) | ||||
| 0 | 2 | 0.10 | 1 | 0.10 |
| 1 | 594 | 36.40 | 678 | 46.70 |
| 2 | 512 | 31.40 | 497 | 34.20 |
| 3 | 268 | 16.40 | 130 | 9.00 |
| 4 | 110 | 6.80 | 51 | 3.50 |
| 5 | 50 | 3.10 | 29 | 2.00 |
| Missing | 94 | 5.80 | 67 | 4.60 |
| Overall mortality at 6 months | ||||
| 317 | 12.90 | 123 | 5.80 | |
SES—socioeconomic status.